FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
ERWIN ROBERT L
   2. Issuer Name and Ticker or Trading Symbol
iBio, Inc. [IBIO] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
President
(Last)
(First)
(Middle)
C/O NOVICI BIOTECH LLC, 3333 VACA VALLEY PARKWAY		 3. Date of Earliest Transaction (Month/Day/Year)
02/20/2019
(Street)

VACAVILLE, CA 95688		 4. If Amendment, Date Original Filed(Month/Day/Year)
 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)		 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)		 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)		 6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)		 7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)		 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)		 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)		 6. Date Exercisable and Expiration Date
(Month/Day/Year)		 7. Title and Amount of Underlying Securities
(Instr. 3 and 4)		 8. Price of Derivative Security
(Instr. 5)		 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)		 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)		 11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $ 6.6 02/20/2019   D     25,000   (1) 08/10/2019 Common Stock 25,000 (2) 232,500 (6) D  
Stock Option (right to buy) $ 0.93 02/20/2019   A   18,750     (3) 02/20/2024 Common Stock 18,750 (4) 232,500 (6) D  
Stock Option (right to buy) $ 17.3 02/20/2019   D     30,000   (5) 08/16/2019 Common Stock 30,000 (2) 232,500 (6) D  
Stock Option (right to buy) $ 0.93 02/20/2019   A   22,500     (3) 02/20/2024 Common Stock 22,500 (4) 232,500 (6) D  
Stock Option (right to buy) $ 19.6 02/20/2019   D     30,000   (1) 10/21/2021 Common Stock 30,000 (2) 232,500 (6) D  
Stock Option (right to buy) $ 0.93 02/20/2019   A   22,500     (3) 02/20/2024 Common Stock 22,500 (4) 232,500 (6) D  
Stock Option (right to buy) $ 11 02/20/2019   D     30,000   (1) 07/24/2022 Common Stock 30,000 (2) 232,500 (6) D  
Stock Option (right to buy) $ 0.93 02/20/2019   A   22,500     (3) 02/20/2024 Common Stock 22,500 (4) 232,500 (6) D  
Stock Option (right to buy) $ 5 02/20/2019   D     30,000   (1) 07/16/2023 Common Stock 30,000 (2) 232,500 (6) D  
Stock Option (right to buy) $ 0.93 02/20/2019   A   22,500     (3) 02/20/2024 Common Stock 22,500 (4) 232,500 (6) D  
Stock Option (right to buy) $ 10 02/20/2019   D     60,000   (7) 09/05/2024 Common Stock 60,000 (2) 232,500 (6) D  
Stock Option (right to buy) $ 0.93 02/20/2019   A   45,000     (3) 02/20/2024 Common Stock 45,000 (4) 232,500 (6) D  
Stock Option (right to buy) $ 17.2 02/20/2019   D     75,000   (7) 09/04/2025 Common Stock 75,000 (2) 232,500 (6) D  
Stock Option (right to buy) $ 0.93 02/20/2019   A   56,250     (3) 02/20/2024 Common Stock 56,250 (4) 232,500 (6) D  
Stock Option (right to buy) $ 4 02/20/2019   D     30,000   (7) 05/01/2027 Common Stock 30,000 (2) 232,500 (6) D  
Stock Option (right to buy) $ 0.93 02/20/2019   A   22,500     (3) 02/20/2024 Common Stock 22,500 (4) 232,500 (6) D  

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
ERWIN ROBERT L
C/O NOVICI BIOTECH LLC
3333 VACA VALLEY PARKWAY
VACAVILLE, CA 95688		       President  

Signatures

 /s/ Robert L. Erwin   05/13/2019
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Vested in five annual instalments on anniversaries of date of grant.
(2) On 2/20/19, the issuer canceled, pursuant to the issuer's option exchange program, old stock options in exchange for new stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including the cancelation of this option grant to the reporting person in exchange for new options.
(3) Fully vests on first anniversary of grant date.
(4) On 2/20/19, the issuer issued new stock options, pursuant to the issuer's option exchange program, in exchange for old stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including this option grant to the reporting person.
(5) Vested 20% on 7/1/2010 and then in 20% instalments on each anniversary thereof.
(6) Reflects number of securities beneficially owned following all transactions reported on this Form 4.
(7) Vested in three equal annual instalments on the anniversary of the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.